Heleen van Ommen

Dr. Heleen van Ommen is an Associate Professor and active researcher in the Department of Pediatrics at Erasmus MC, Faculty of Medicine. Her work is centered on pediatric hematology, with a strong focus on venous thromboembolism, anticoagulation therapy, and extracorporeal membrane oxygenation (ECMO). She contributes significantly to clinical guidelines and multicenter research collaborations, particularly in hemostasis and thrombosis in children.

Her research interests span pediatric thrombosis, anticoagulation strategies, ECMO-related hemostatic challenges, and systematic reviews of clinical trials. She is deeply involved in standardizing outcome definitions and improving safety in anticoagulated pediatric patients. Her work often bridges clinical practice with evidence-based medicine, influencing international guidelines.

The analysis of her recent publications reveals a consistent focus on pediatric venous thromboembolism, anticoagulant monitoring, and methodological rigor in clinical research. Her contributions include high-impact guidelines, cohort studies, and systematic reviews published in top journals such as Blood Advances and The Lancet Respiratory Medicine.

Scientific Contributions:

• Co-author of ASH/ISTH 2024 pediatric VTE treatment guidelines
• Lead investigator in multicenter studies on ECMO anticoagulation
• Active contributor to pediatric DOAC trial methodology
• Research on bleeding severity scales and D-dimer utility in children

Dr. van Ommen has supervised academic work, as indicated by one recorded supervised project. She participates in extensive national and international collaborations, particularly with centers in Melbourne and Rotterdam. Her research is widely recognized, with uptake by numerous news outlets and social media platforms, reflecting its clinical relevance and impact.

She is involved in research networks focusing on pediatric hemostasis, contributing to both clinical studies and methodological advancements. Her work is integral to improving outcomes in critically ill children requiring anticoagulation.